secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sensei Biotherapeutics, Inc. (SNSE)
CIK:        0001829802
Form:       8-K
Filed at:   2026-08-04T11:40:27+00:00
Accession:  0001193125-26-331563
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Faeth Therapeutics Q2 2026 net loss $16.0M; cash $186.4M; Phase 2 PIK-201 data expected year-end
--------------------------------------------------------------------------------

- Net loss of $16.0M ($2.84 per share) for Q2 2026, compared to $4.9M ($3.91 per share) in Q2 2025.
- Cash, cash equivalents and marketable securities of $186.4M as of June 30, 2026, up from $21.2M at Dec 31, 2025, reflecting $200M PIPE financing.
- Topline results from Phase 2 PIK-201 trial in endometrial cancer on track for year-end 2026.
- First patient dosed in Phase 1b/2 PIK-101 trial in HR+ breast cancer in April 2026.
- Company changed name to Faeth Therapeutics and began trading under ticker FTH on June 16, 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526331563/0001193125-26-331563-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1829802/000119312526331563/d168633d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-331563

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer